Endometrial hyperplasia: a prospective randomized study of histopathology, tissue steroid receptors and plasma steroids after abrasio, with or without high dose gestagen treatment.
274 patients with spontaneous endometrial hyperplasias were randomized into two groups: one treated with only abrasio, and another with additional 500 mg medroxyprogesterone acetate (MPA) twice weekly for 3 months. Total disappearance of all types of hyperplasias was seen following MPA treatment, whereas with only abrasio about 60% were removed suggesting that MPA does not have to be generally given to eliminate endometrial hyperplasias. Quantitative determinations of tissue steroid receptors and plasma steroids do not seem to be useful for the selection of patients in need of gestagen treatment.
Lindahl
B
B
Department of Obstetrics and Gynecology, Oncology University Hospital, Lund, Sweden.
Alm
P
P
Fernö
M
M
Norgren
A
A
D000735:Androstenedione / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004714:Endometrial Hyperplasia / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D004958:Estradiol / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D011374:Progesterone / Q000097:blood*; D011446:Prospective Studies; D011897:Random Allocation; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000735:Androstenedione; D011374:Progesterone; D004958:Estradiol; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone